Endometrial Cancer Trial, Recruiting NCT04929769 Sponsor: Obstetrics & Gynecology Hospital of Fudan University Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT04929769
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of cervical cancer (squamous carcinoma, adenocarcinoma, or squamous adenocarcinoma) at an early stage (Stage IB1, IB2, or IIA1)
  • People aged 21 to 70 years old
  • People whose planned surgery falls under a specific surgical classification known as Type B or C (the trial site can confirm what this means for an individual case)
  • People whose blood test results fall within acceptable ranges, including healthy enough levels of red blood cells, platelets, white blood cells, kidney function markers, and liver function markers
  • People with no history of any other type of cancer
  • People who are not pregnant
  • People who have a physical fitness score of at least 60 on the Karnofsky scale, meaning they are reasonably able to carry out daily activities (the trial site can assess this)
  • People who are willing to take part, sign a consent form, and attend follow-up appointments
  • People who do not have a psychiatric disorder or a serious immune system condition such as lupus, myasthenia gravis, or HIV

Who may not be able to join:

  • People who have a medical reason that prevents them from having surgery
  • People who have previously received radiotherapy to the pelvis or abdomen, or chemotherapy given before surgery, for cervical cancer
  • People whose cervical cancer has come back after previous treatment
  • People whose scans (CT, MRI, or PET-CT) show signs of possible cancer spread to pelvic lymph nodes larger than 2cm in size

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xin Wu, PHD, The Obstetrics and Gynecology Hospital of Fudan University

Phone: (021)33189900-6529

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Obstetrics & Gynecology Hospital of Fudan University
Registry
ClinicalTrials.gov
Start date
7 May 2021
Est. completion
7 September 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

the rate of PFS at 5 years

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov